Current treatment strategies in ANCA-positive renal vasculitis-lessons from European randomized trials
Language English Country England, Great Britain Media print
Document type Journal Article, Review
PubMed
12817056
DOI
10.1093/ndt/gfg1032
Knihovny.cz E-resources
- MeSH
- Glomerulonephritis complications diagnosis therapy MeSH
- Immunosuppressive Agents administration & dosage MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- Plasmapheresis methods MeSH
- Prognosis MeSH
- Antibodies, Antineutrophil Cytoplasmic analysis MeSH
- Randomized Controlled Trials as Topic MeSH
- Severity of Illness Index MeSH
- Vasculitis complications diagnosis therapy MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Geographicals
- Europe MeSH
- Names of Substances
- Immunosuppressive Agents MeSH
- Antibodies, Antineutrophil Cytoplasmic MeSH
Antineutrophil cytoplasmic antibody (ANCA)-positive renal vasculitis is the most common cause of rapidly progressive (crescentic) glomerulonephritis. Its life-threatening natural course may be modified substantially by current treatment modalities. The European Vasculitis Study Group (EUVAS) developed a subclassification of ANCA-positive vasculitides based on the disease severity at presentation, and have organized (so far) two waves of clinical trials. The first wave of randomized clinical trials had the aim of optimizing the existing therapeutic regimens; the second wave concentrated on testing some newer therapeutic approaches. Here, the design and available results of the first wave and the design of some second wave trials are reviewed briefly. The potential of the new targeted approaches (e.g. anti-tumour necrosis factor therapy) is also briefly mentioned.
References provided by Crossref.org
